Gilead, which was first to market with its hepatitis C cure Sovaldi late last year and has been racking up about $3 billion in sales each quarter, is a solid bet to be among the leaders in the next wave of liver therapies, experts said.
And yes..... please sell and get on with you life.....and do not waste time on this..... if you do not believe in a cure for Nash is here....since... Intercept believes they have something better than their company and they have the cure for Hep. C. I Believe they would know since they are in the race also to cure Nash.......and believe Galectin has the answer and FDA has FAST TRACT...Galt.......
continue to read
The articles were written by Emerging Growth LLC using only information in the public domain and comparing and contrasting Galectin's program with others in the field. Disclaimers were provided by Emerging Growth LLC that Galectin paid $3500 monthly for this service. The characterization that this practice is a "scheme," implying an illegal activity, is just not correct. Again, we believe our decision to contract for certain public relations activities, rather than attempting to staff them in-house, is a legal, appropriate and prudent use of our resources.
About Fatty Liver Disease with Advanced Fibrosis
Non-alcoholic steatohepatitis (NASH), also known as fatty liver disease, has become a common disease of the liver with the rise in obesity rates, estimated to affect nine to 15 million people, including children, in the U.S. Fatty liver disease is characterized by the presence of fat in the liver along with inflammation and damage in people who drink little or no alcohol. Over time, patients with fatty liver disease can develop fibrosis, or scarring of the liver, and it is estimated that as many as three million individuals will develop cirrhosis, a severe liver disease where liver transplantation is the only current treatment available. Approximately 6,300 liver transplants are done on an annual basis in the U.S. There are no drug therapies approved for the treatment of liver fibrosis.
About Galectin Therapeutics
Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver
NORCROSS, Ga., July 30, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced yesterday results of cohort 2 of its phase 1 clinical trial in patients with NASH with advanced fibrosis. While the results of the clinical trial were positive, the market reacted negatively to this report. We believe the reaction was fueled in part by certain commentary on social media sites and the Internet and we strongly disagree with these interpretations of our data. Our goal in commenting further at this juncture is to provide clarity and a helpful framework for investors on the long-term outlook of the company and our work toward developing potential therapies for NASH and liver fibrosis.
GR-MD-02 is a complex carbohydrate molecule derived from apple pectin material that binds to galectin-3 protein thereby inhibiting its activity. There is a large amount of scientific literature showing galectin-3 is a critical protein in fibrosis. While certain commentators on social media sites have dubbed it a "non-mechanism of action," this view contradicts many peer reviewed published studies. The phase 1 clinical trial was the first time this molecule was infused into man. Comments on social media about the drug being a "sugar placebo" are misguided and anti-intellectual. GR-MD-02 has been shown to be effective in treating NASH and fibrosis when infused in several animal models, results of which have been reported in peer review scientific journals and presented at international scientific meetings. Based on the pre-clinical data and the enormous need for drugs in an area where there is no therapy, the FDA gave development of GR-MD-02 for NASH with advanced fibrosis Fast Track designation. The importance of galectin-3 in fibrosis and the mechanism of action and the drug action are on a firm scientific foundation.
Certain commentators on social media labeled the second cohort r
I do know what I read on Fidelity and your report is different and I do not know who Adam is, so why would he say Hello to a stranger? I Believe you are not at all interested in the cure for Nash and just do this to cause dissension. Shalom to you
I never read where the placebo was more effective, so where did you read this at? You would not have the doctors or FDA fast forward if this was true...... the clinical would have ended showing a failure if the placebo was more effective. a placebo cannot reverse liver disease believe me...........FDA would not be interested if a placebo was really move effective. Think about what you are saying.
what works in mouse and rat models usually works well in humans since the anatomy structure is like humans etc..
Whether in the lead or not in clinical development of a NASH drug, Intercept is the topic of some overzealous analyst price targets that are a reason for caution without a complete set of clinical data. This includes Bank of America Merrill Lynch’s (NYSE:BAC) jaw-dropping price-target hike from $81 to $872 the day after the Phase 2 data news hit. If conclusions are to be drawn so early in the game, it’s arguable that Intercept’s peer Galectin Therapeutics may actually have a better NASH/fibrosis drug in GR-MD-02, based upon several factors.
Galectin has developed a technology platform in which its complex carbohydrate-based compounds are built upon a proprietary method of targeting galectin proteins — key mediators of biologic and pathologic function – to bind with them and inhibit their function. Galectin proteins have been proven to play an important role in the development and promotion of fibrotic, inflammatory and neoplastic diseases. In most healthy cases, the proteins are relatively few in number, but in diseased states galectin proteins are more abundant.
The company’s flagship fibrosis drug, GR-MD-02 is in a Phase 1 clinical trial for NASH patients with advanced liver fibrosis. The FDA granted Galectin a Fast Track designation to expedite development of GR-MD-02 for the indication in August. Patient enrollment has been completed for the first cohort, with data expected by the end of March. Data from the third and final cohort of the trial is anticipated early in the fourth quarter this year.
Laboratory research in mouse and rat models delivered data showing robust efficacy of GR-MD-02 in not only stalling the advance of liver fibrosis, but in actually reversing the condition. Additional preclinical research suggested that the drug candidate could also potentially serve a therapeutic benefit in lung and kidney fibrosis patients.
I believe that one of the clinical trials was done at IU...Medical Center in Indianapolis if you check. In addition, I was told by the transplant doctor that in the next 10 or 15 years they will not be doing liver transplants. I had ask why we do not do the stem cells you grow from your own body and inject back into the liver.( other countries were having clinical trials on these). This is when he told me this, so they know a cure is coming. I contacted a professor at John Hopkins about her research on this and asked when she would do the clinical trials. She said FDA will not let her do them now and there will be a drug used first.....we would see this come first and then she will most likely be able to do her trials. Also talked to California research which sent patients to Mexico for peptide & amino treatments...which an American Pharmacist called me back and talked to me about this. Insurance will not cover Mexico and not sure going there would be safe. Only way you can go is if they Fly you there from Arizona or California...in and out.. We were looking for a Clinic Trial , but his hematologist said they would never let him do one since the blood disease is present (adding a factor to the conditions) and would or could cause a clinical trial failure in one patient and that would not look good for the drug.
Do you really know anything at all about liver disease or understand what goes on inside with the portopulmonary hypertension, hepatopulmonary syndrome, ascites ,paracentesis, etc or the complications or how to control it with food and other products? And do you realize it can cost you $8000 a week to have a paracentesis and how this drug will keep people from having to go through all this.
I had done the reasearch and showed it to the doctor and he knew about it at the time.....Husband died do not see them.....now....was trying to get a liver transplant, but they could not control the lung pressure. Hepatopulmonary. syndrome... Complication of the liver problem... Blood treatment ruined the liver..with cirrhosis....reaction to it....
(Taken from Intercept's writing on Galt)..........(LOOK)...........
Galectin Therapeutics (GALT) had preclinical studies showing good results. The compound GR-MD-02 significantly improved NASH activity and reduced fibrosis including prevention of accumulation of collagen and/or reduced accumulated collagen in the liver. With no approved treatments for fatty liver disease with fibrosis, the results appear significant. So look at what kind of loss Intercept is reporting and they are still running for the race but believes Galt has potential....so could have Galt been target on purpose for a fall for lawsuits by creating confusion since they have the cure and it is a matter of time....I know in 2012 some Liver experts in Indiana thought they were on to something.
Intercept reported a loss of $55.4 million, or $3.15 per share, for the nine months ended September 30, 2013, compared to a net loss of $15.5 million, or $4.64 per share, for the nine months in the year before.
If you read and understand the liver language and what is going on this will be great.....I do.....looks very promising........
They do have a good product if you know anything about this...I do know from personal experience from a sickness in our family and the product just needs to be marketed....Lifesavers for future health in blood disease and Ischemic ulcers......etc
The whole crash was probably to try and discredit so the competition could try and get the first drug approved for Nash or it is all about the stock money made and these people do not really care about the cure for liver disease. Time will tell......